NCT04465916 - Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

June 17, 2021

Study Completion Date

November 25, 2021

Conditions

Hepatitis B, Chronic

Interventions

DRUG

EYP001a

Oral tablets

DRUG

Placebo

Oral tablets

DRUG

Nucleotide analogue (Entecavir or Tenofovir Disoproxil)

Oral tablets

Trial Locations (18)

ENYO PHARMA Investigative site AU02, Brisbane

ENYO PHARMA Investigative site AU01, Melbourne

ENYO PHARMA Investigative site AU03, Melbourne

ENYO PHARMA Investigative site AU04, Melbourne

ENYO PHARMA Investigative site HK01, Hong Kong

ENYO PHARMA Investigative site PL01, Bialystok

ENYO PHARMA Investigative site PL06, Kielce

ENYO PHARMA Investigative site PL05, Lodz

ENYO PHARMA Investigative site PL02, Lublin

ENYO PHARMA Investigative site PL03, Warsaw

ENYO PHARMA Investigative site PL04, Zawiercie

ENYO PHARMA Investigative site KR04, Pusan

ENYO PHARMA Investigative site KR07, Pusan

ENYO PHARMA Investigative site KR05, Seongnam

ENYO PHARMA Investigative site KR01, Seoul

ENYO PHARMA Investigative site KR02, Seoul

ENYO PHARMA Investigative site KR03, Seoul

ENYO PHARMA Investigative site KR06, Seoul